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HMrazCPI was found to be an inhibitor of human liver cathepsin H by the measurement of the 
dissociation constant (K,), the association rate constant (kl) and the dissociation rate constant (k-1) 
between the enzyme and the inhibitor. These data suggest hat this protein-proteinase inhibitor can play 
a physiological role in the regulation of free cathepsin H. 
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1. INTRODUCTION 2. MATERIALS AND METHODS 
The inhibitory properties of HMraKPI are 
under investigation in our laboratory and it has 
been found that human liver cathepsin L is con- 
trolled by this protein-proteinase inhibitor [l]. A 
quantitative analysis of the interaction has been 
described [2]. On the other hand, this protein is 
also able to inhibit human liver cathepsin H (EC 
3.4.22.16). The physiological significance of this 
phenomenon has been shown by a study of the 
equilibrium between the enzyme and the inhibitor. 
In spite of the lack of inhibition of human liver 
cathepsin B [3-51 HMra2CPI seems to be a com- 
ponent in the regulatory pathway for lysosomal 
cysteine proteinases. 
Pleural fluids were used for the preparation of 
HMrc&PI. Disease-free human liver, stored at 
-20°C until required, was used for the prepara- 
tion of cathepsin H. Papain, ficin, BzArgNNap, 
LeuNNap , ammonium sulphamate, sodium 
nitrite, N-(1-naphthyl)ethylene diamine and ,8- 
naphthylamine were purchased from Sigma (St 
Louis, MO). CNBr-activated Sepharose, Blue 
Sepharose (F3GA) Sephadex-G75 superfine, 
DEAE-Sephadex-A50 and Sephacryl S200 super- 
fine were supplied by Pharmacia (Uppsala). 
Aldolase activity was assayed with the Boehr- 
inger UV system (Mannheim). E 64 and ArgNMec 
were supplied by the Protein Research Foundation 
(Osaka). 
Abbreviations: HMraKPI, cy2 cysteine proteinase in- 
hibitor, high-M,; C.H, cathepsin H (EC 3.4.22.16); 
B,ArgNNap, N-benzoyl-DL-arginine-2-naphthylamide 
hydrochloride; ArgNNap, L-arginine-2-naphthylamide 
hydrochloride; LeuNNap, L-leucine-2-naphthylamide 
hydrochloride; ArgNMec, L-arginine-4-methyl-7- 
coumarylamide; E 64, L-trans-epoxysuccinyl-leucyl- 
amido(4-guanidino)butane; pZ, isoelectric point; DTT, 
1,4-dithioerythreitol 
2.1. Purification and titration of HiWcdPI 
This protein was isolated as in [ 1,2]. The effec- 
tive molarity of the purified inhibitor was deter- 
mined by titration with papain after active site 
titration of this proteinase by E 64 [2]. 
2.2. Preparation of human liver cathepsin H 
The enzyme was purified by a modification of 
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the method described for cathepsin B and L [l]. 
Homogenisation, precipitation with ammonium 
sulphate and dialysis were unchanged. These were 
followed by ion-exchange chromatography on a 
DEAE-Sephadex column. The purification was 
compIeted by two consecutive gel filtrations on a 
Sephadex-G75 (superfine) column (2.5 x 75 cm). 
The purified enzyme was tested against ArgN- 
Nap, LeuNNap, BzArgNNap, aldolase and azoca- 
sein as described for cathepsin B and L in [l]. The 
activity against ArgNMec was carried out as in [7]. 
The effective molarity of this enzyme was deter- 
mined by using E 64 as in [8]. Acrylamide gel elec- 
trofocusing and acrylamide gel electrophoresis in 
the presence of sodium dodecyl sulphate were per- 
formed as in [9] and [IO], respectively. 
All proteinase and inhibitor concentrations 
given in this paper refer to ‘active concentrations’. 
2.3. Titrations of human liver cathepsin H by 
HMraXPI 
Cathepsin H (0.1 x 10e6 M) was incubated for 
10 min at 25°C with increasing amounts of 
HMrazCPI (0.34 x lo-’ M-O.66 x 10e6 M) in 
0.1 M sodium phosphate buffer (pH 6.8), 2 mM 
EDTA, 1 mM DTT (final vol. 100~1) before ad- 
ding 10~1 of 3 x 10e3 M ArgNNap (S, = 30 k,). 
After 10 min at 40°C the reaction was stopped 
and samples were processed as in [ 11. 
2.4. K, determination 
We have used the Easson-Stedman plot [ll]. 
The non-linearity of the titration curve was obtain- 
ed by working with a more dilute enzyme. This was 
possible with ArgNMec as a substrate. 
Cathepsin H (0.2 x lO-7 M) was incubated with 
HMrtvzCPI (0.68 x lo-’ M-l.7 x 10s7 M) under 
the conditions described above. Ten ~1 of 1 x 
low4 M ArgNMec (S, = 6.6 &) was then added. 
After 15 min at 4O”C, the residual enzymatic ac- 
tivity was measured as in [S]. 
The same experiment was carried out with 3 dif- 
ferent substrate concentrations (S, = 0.66, 3.3, 
6.6 Ktn). 
2.5. kr determination 
The association rate constant was determined 
under second order conditions [ 121. Equimolar 
concentrations of enzyme and inhibitor (1 x 
lo-’ M) were mixed in 5 ml (final vol.) of activa- 
tion buffer at 25°C; 200~1 of the mixture was 
removed at the times 0, 1, 3, 5, 8, 10 min and 
assayed with ArgNMec (10~1, S, = 3.3 &,) which 
stops the reaction and measures the residual en- 
zymatic activity. 
2.6. k-1 determination 
The dissociation equilibrium study was carried 
out by complex dilution [13]. The complex bet- 
ween the enzyme and the inhibitor was obtained by 
allowing to react equimolar concentrations of both 
partners (0.2 x lob6 M) during 10 min at 40°C 
(final vol. lOO$). 
This was followed by adding 1.9 ml of activa- 
tion buffer. The increase in enzymatic activity was 
measured by removing 200 pi of this mixture at the 
times 0, 10, 20, 30, 45 and 60 min. The portions 
removed were assayed with ArgNMec (10~1, S, = 
3.3 K,,,) as described before. 
For the estimation of the total enzymatic activi- 
ty, a control was made up in the same way, but 
without inhibitor. 
Calculations were carried out by using: 
control - measurement l-a El ~=- 
control 1 El, 
3. RESULTS 
3.1. Titration of HMro$PI 
This purified inhibitor was found to be 6.9 X 
10e6 M active for a protein concentration of 16 x 
10m6 M; i.e., 43% of this inhibitor was active. 
3.2. Characterization of human liver cathepsin H 
The purification method gave an enzyme, 
purified about 600-fold. By acrylamide gel elec- 
trofocusing (pH gradient 3.5-10) one band at pI 
6.20 was found when the staining was carried out 
with Coomassie brilliant blue. By an activity- 
staining method using ArgNNap the same pattern 
was obtained (fig.1). The most important proper- 
ties of this enzyme are summarized in table 2: the 
high aminopeptidase and endopeptidase activities 
accompanied by a low proteolytic activity were in 
agreement with [6]. 
By active site titration, this enzyme was found to 
be 50% active. The operational molarity was 9.5 x 
10m6 M for a protein concentration of 19 x 
10e6 M. The specific activities reported in table 1 
refer to the active fraction. 
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6.20 - -6.20 
a b 
Fig. 1. Gel electrofocusing of purified cathepsin H (25 pg 
sample). The experiment was carried out over a pH 
gradient 3.5-10.0. (a) Staining for enzymic activity with 
ArgNNap as a substrate. (b) Staining with Coomassie 
brilliant blue after incubation for activity staining. 
3.3. Titration of human liver cathepsin H by 
HMrwCPI 
The inhibition of cathepsin H activity (0.1 x 
10m6 M) upon addition of increasing amounts of 
Table 1 
Some properties of human liver cathepsin H 
Specific activities (units/mg at pH 6.8) against 
ArgNMec 2.2 
ArgNNap 1.8 
LeuNNap 1.1 
BzArgNNap 1.0 
Azocasein 0.1 
Aldolase 0.14 x 1o-3 
p% 
28Onm,lcm 
M, value 
11.80 
26000 
Isozymes 
Number 1 
PI 6.20 
1 
a 
0.5 
0 
Fig.2. Residual fractional activity (a = Vi/l’,) of 
cathepsin H (0.1 x 10m6 M) on ArgNNap upon addition 
of HMrc&PI (0.34 x lo-* M-O.66 x 10e6 M). 
HMrazCPI gives a linear titration curve (fig.2). 
This result is consistent with a 1: 1 association bet- 
ween both partners. As has been shown in [14] for 
reversible reactions, conditions for obtaining a 
linear titration curve are fulfilled when &/Ki > 
100. These data allow us to suppose a low Ki value. 
3.4. Ki determination for cathepsin H and 
The dissociation constant (KJ is determined by 
using the reversibility of the reaction. When work- 
ing at a low enough enzyme concentration a rever- 
sibility of the proteinase-inhibitor association is 
observed [13]. Data were plotted as in [14] and the 
slope of the straight line obtained corresponded to 
app. Ki (fig.3). In this case, substrate-induced 
dissociation was found by using 3 different 
substrate concentrations. When plotting app. Ki vs 
So, the intercept on the ordinate gives the true K, 
value [14] (fig.3). 
The interaction between human liver cathepsin 
H and HMrazCPI was characterized by Ki = 9.0 x 
lo-” M. On the other hand, the replot app. Ki vs 
S, indicates a competitive inhibition [14]. 
3.5. kl determination for cathepsin H and 
HiWrcz2CPI 
For the calculations of the association rate cons- 
tant, concentrations of enzyme and inhibitor used 
are low enough to study the time-dependency of 
the reaction. Working under second-order condi- 
tions, and assuming a simple reversible 
64 
Volume 166. number 1 FEBS LETTERS January 1984 
2 
b M.107 
i-a 
Fig.3. Determination of app. K, according to the 
followina eauation: 
10 Xi &p ~ = -- + Eo [11,14]. 
1-U 
The residuz fractional activity a = Vi/l’, of cathepsin 
H (0.2 x 10m7 M) on ArgNMec was determined with 
increasing concentrations of HMrcvzCPI (0.68 x 
1O-8-1.7 x low7 M). The insert shows the true Ki value 
which was calculated from: 
app. Ki = K, + K$ [14]. 
m 
equilibrium, the findings may be analyzed as in 
[13] (fig.4). We have found a kt value of 2.0 x 
10m6 M-‘.s-~). We have also estimated the delay 
time, i.e., the time required for complete inhibition 
of a proteinase in vivo [ 131, by using an ex- 
0 ’ I 
5 10 
t min 
Fig.4. Time-dependency of the inhibition of human liver 
cathepsin H by HMrcvzCPI (1.0 x 10m8 M for both 
partners). The insert is a second order replot according 
to: 
1 1 
= - + k,t [13] 
E & 
0 ’ I 
30 
t milr; 
Fig.5, Dissociation of the cathepsin H-HMraKPI 
complex by dilution. The enzyme and the inhibitor 
(0.20 x 10e6 M) were preincubated during 10 min at 
40°C (100 ~1 final vol.); 1.9 ml of activation buffer was 
then added and enzymatic activity was monitored 
against time. The insert is the first order replot according 
to: 
log; = -kit [13] 
0 
travascular concentration of 5.5 x lop6 M for 
HMrazCPI [2]. This result was found to be 2 s. 
3.6. k-1 determination for cathepsin H and 
HMrw CPI 
For the measurement of the first order dissocia- 
tion rate constant, the enzyme and the inhibitor 
were mixed at equivalent concentrations (0.2 x 
10m6 M). High concentrations were used in order 
to carry out a complete association between both 
partners. After a sufficient preincubation time, a 
large volume of buffer was added to induce the 
dissociation process. The increase in enzymatic ac- 
tivity is followed as a function of time. The results 
are plotted as in [ 131. We have found a k-1 value 
of 1.0 x 10-3.s-1 (fig.5). The stability time, i.e., 
the time during which the complex remains un- 
dissociated in vivo [ 131, was found to be 3 min. 
4. DISCUSSION 
HMrcyzCPI inhibits human liver cathepsin H. 
The results reported here are consistent with this 
interaction being physiologically significant. The 
inhibitor binds the enzyme fast enough and the 
I, : Ki ratio is very high (table 2). If this enzyme is 
liberated during inflammatory states, it will be 
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Table 2 
Kinetic constants for the interaction of HM~(uzCPI with cathepsin H 
January 1984 
Ki (W Kl Delay time K-1 Stability Io/Ki 
(M-‘.s-‘) (s) (s-l) time (min) 
9.0 x lo-lo 2 x lo6 2 1.0 x 1o-3 3 6.0 x lo3 
complexed by HMrc&PI. It is surprising that the 
function of this inhibitor has not been discovered 
before. The lack of inhibition of human liver 
cathepsin B [3-51 may explain these negative in- 
vestigations. We have found that human liver 
cathepsin L is also inhibited by HMr&ZZPI with a 
high efficiency [2]. The specificity of this inhibitor 
would be restricted to both lysosomal cysteine 
proteinases? 
On the other hand, the tight binding of papain 
by HMrazCPI (Ki - lo-” M) demonstrates the ex- 
istence of a structural analogy between plant and 
mammalian cysteine proteinases, cathepsin H and 
L seeming to have a common binding site for 
HMraXPI with papain. This site, however, does 
not seem to exist on cathepsin B. But cathepsin B 
and papain have an extremely high sequence 
analogy in the active site region [ 151. Thus it seems 
that the binding site for HMr&ZPI is not located 
in the active site region. 
We have found a competitive inhibition for both 
lysosomal cysteine proteinases ([2], here). This 
result can be explained by bound inhibitor overlap- 
ping the active site. This is consistent with the high- 
IU, of HMrazCPI. Cathepsin H is an endopep- 
tidase as well as an aminopeptidase and both ac- 
tivities may provoke tissue damage during inflam- 
matory reactions. The presence of HMra2CPI out- 
side the circulation (e.g., in pleural and ascitic 
fluids) dispels any doubt on the physiological role 
of this inhibitor. However, this protein is not an 
‘acute phase reactant’ in the human [2], but in the 
rat it is identical with cyi acute phase globulin [16]. 
The recent report of [17] shows that the sequence 
of cathepsin H is more closely related to that of pa- 
pain than the sequence of cathepsin B. Our fin- 
dings fit in well with the structural homology bet- 
ween papain and cathepsin H and underline the 
structural differences between papain and cathep- 
sin B. 
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